Antibody response to mRNA SARS-CoV-2 vaccine among dialysis patients—a prospective cohort study
Timna Agur, Naomi Ben-Dor, Shira Goldman, Shelly Lichtenberg, Michal Herman‐Edelstein, Dafna Yahav, Benaya Rozen‐Zvi, Борис Зингерман
Abstract
Emerging data has established end-stage renal disease (ESRD) as one of the highest risk comorbidities for severe coronavirus disease 2019 (COVID-19), with short-term mortality above 20% Based on both a large clinical trial and real-life data from Israel in the general populations, the effectiveness of mRNA-based BNT162b2 vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was estimated at 95% Nevertheless, dialysis patients present diminished immune response following immunization with various vaccines, and the efficacy of the available SARS-CoV-2 vaccine among this vulnerable group is unknown Therefore, we performed a prospective study, evaluating antibody response among hemodialysis and peritoneal dialysis (PD) patients 2-6 weeks after receiving the second dose of BNT162b2.